Oxybutynin ER

ApprovedSmall molecule

FFar Eastern Memorial Hospital

Oxybutynin ER is one of 73 small molecule programs targeting Cognition. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

Overactive BladderActive, not recruiting

CognitionApproved

Active, not recruiting

Overactive BladderPhase 3

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Cognition

#DrugCompanyPhaseTrials

Oxybutynin ER

FFar Eastern Memorial Hospital

Approved

1 2

Activella

Eli Lilly

Preclinical

2 3

Estrace

Novo Nordisk

Preclinical

2 4

Ozempic

Novo Nordisk

Preclinical

1 5

Galvus

Novartis

Preclinical

1 6

Depo-Provera

Pfizer

Preclinical

1 7

Resotran

Takeda

Preclinical

1 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 9

Marinol

Alnylam Pharmaceuticals

Preclinical

1 10

Veramyst

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Overactive Bladder

NCT07114640

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms

Unknown status·—·Phase 3·NCT05637671·146 enrolled

OnabotulinumtoxinA1 trial

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Unknown status·CChristopher Patrick Smith·Phase 3·NCT01050114·36 enrolled

Overactive Bladder1 trial

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Not yet recruiting·FFar Eastern Memorial Hospital·Phase 3·NCT07114640·220 enrolled

Cognition1 trial

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00411437·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Oxybutynin ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxybutynin ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxybutynin ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Far Eastern Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFar Eastern Memorial Hospital

Oxybutynin ER

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Efficacy and Safety1 trial

OnabotulinumtoxinA1 trial

Overactive Bladder1 trial

Cognition1 trial

References

Drug Info

Quick Facts

Related News